Germany is experiencing a surge in respiratory illnesses, including colds, influenza, and COVID-19, according to RND.de. Health authorities attribute the rise to seasonal factors and waning immunity, emphasizing vaccination and hygiene as critical measures.
Why the Surge? Epidemiological Insights
Public health data from the Robert Koch Institute (RKI) indicates a 22% increase in respiratory infections compared to the same period in 2025. This aligns with global trends of seasonal viral co-circulation, where rhinoviruses (common colds), influenza A/H1N1, and SARS-CoV-2 variants like BA.5.2 dominate. Dr. Lena Winkler, RKI epidemiologist, notes, “The overlap of these pathogens strains diagnostic capacity and highlights the need for integrated surveillance.”
The European Medicines Agency (EMA) has approved updated seasonal vaccines, including a quadrivalent influenza formulation and a bivalent SARS-CoV-2 booster. However, vaccination rates in Germany remain below the 75% target set by the World Health Organization (WHO), with only 68% of the population fully immunized as of May 2026.
In Plain English: The Clinical Takeaway
- Multiple viruses are circulating: Colds, flu, and COVID-19 are all contributing to the rise in illness, making symptoms harder to distinguish.
- Vaccines remain effective: Updated formulations target current strains, reducing severe outcomes.
- Prevention is key: Frequent handwashing, mask-wearing in crowded spaces, and avoiding close contact with sick individuals lower transmission risk.
Transmission Dynamics and Regional Impact
Respiratory viruses spread via aerosols and droplets, with influenza and SARS-CoV-2 sharing similar transmission routes. In Germany, the National Health Service (NHS) reports that 45% of cases occur in households, underscoring the role of close contact. The EMA’s guidelines emphasize that PCR tests remain the gold standard for differentiating between pathogens, though rapid antigen tests are useful for initial screening.
Regional disparities exist: Bavaria and North Rhine-Westphalia report higher hospitalization rates, likely due to denser populations and lower vaccination uptake. The German Society of Virology (DSV) warns that co-infections—such as flu and COVID-19—can increase the risk of severe outcomes by 30%, per a 2025 study in The Lancet Infectious Diseases.
| Pathogen | Transmission | Incubation Period | Severe Outcome Risk |
|---|---|---|---|
| Colds (Rhinovirus) | Aerosol, contact | 1–3 days | Low (unless immunocompromised) |
| Influenza A/H1N1 | Aerosol, droplets | 1–4 days | 15% in high-risk groups |
| SARS-CoV-2 (BA.5.2) | Aerosol, contact | 2–7 days | 5% in unvaccinated individuals |
Contraindications & When to Consult a Doctor
Vaccines are generally safe but contraindicated in individuals with severe allergic reactions to prior doses. The German Federal Institute for Drugs and Medical Devices (BfArM) advises against vaccination for those with acute febrile illnesses. Patients should seek immediate care if they experience persistent high fever (>39°C), difficulty breathing, chest pain, or confusion, as these may indicate pneumonia or multisystem inflammatory syndrome.
What’s Next? Public Health Projections
The RKI predicts a peak in
